Dr Geert Groeneveld

Dr Geert Groeneveld

Name:

Dr Geert Groeneveld

Organisation:

Centre for Human Drug Research

Year elected:

2024

Primary professional setting:

Clinical Academia

Prof Geert Jan Groeneveld trained as a neurologist at the University Medical Center Utrecht, where he also obtained his PhD on pharmacological treatment for amyotrophic lateral sclerosis. He subsequently worked for biotechnology company Genzyme where he was responsible for gene therapy programs for Parkinson’s disease and helped to register enzyme replacement therapy for late onset Pompe disease. From 2009 to 2017, he served as Research Director at the Centre for Human Drug Research (CHDR), where he was responsible for early phase drug studies in the areas of neurology and pain. In 2018 Dr Groeneveld joined the board of CHDR and in 2024 he became Chief Executive Officer. In addition to serving on CHDR’s board, he is a professor of Clinical Neuropharmacology at LUMC and sees patients with neurological causes of chronic pain started in the pain outpatient clinic at the Leiden University Medical Center (LUMC). Dr. Groeneveld’s primary scientific interest lies in early-phase drug development for the treatment of neurological diseases and pain. He has published over 140 scientific articles in peer-reviewed journals and is actively involved in the training of PhD students at CHDR. In addition, he is a board-certified clinical pharmacologist and serves on the editorial board of BJCP.